New research suggests the shingles vaccine may offer benefits beyond preventing shingles. Studies indicate Shingrix could reduce the risk of heart disease and delay dementia. These findings add to the growing interest in the vaccine’s broader health effects.
Shingrix is a newer vaccine approved for adults aged 50 and older. It prevents shingles, a painful rash caused by the reactivation of the chickenpox virus. The vaccine has proven highly effective at reducing shingles cases.
Scientists have observed that people who receive Shingrix may have a lower risk of cardiovascular problems. Some studies link the vaccine to fewer heart attacks and strokes. The exact reasons for this connection remain under investigation.
Cognitive health is another area of focus. Research hints that Shingrix might delay the onset of dementia. The vaccine may reduce inflammation or other factors that contribute to cognitive decline. More studies are needed to confirm these potential benefits.
The link between shingles and dementia is not entirely new. The virus that causes shingles can affect blood vessels and nerve tissues. Preventing the virus from reactivating could protect long-term brain health.
Heart disease and dementia are leading causes of illness and death worldwide. A vaccine that addresses both would have significant public health implications. Researchers are calling for larger trials to verify the early findings.
For now, the shingles vaccine is recommended for older adults to prevent shingles and its complications. Any additional protective effects would be a welcome bonus. Patients should consult their doctors about vaccination.
